Jump to Section
INTEGRIS Health, OK (OK)
CUSIP: 45834QAA7
By &Evergreen Team•Updated: Nov 18, 2025
NRCautious
Overview
•Bond Name/Type: INTEGRIS Baptist Medical Center, Inc. – Taxable Health-Care Revenue Bonds, Series 2020A (and parity Master Indenture debt)
•Top-Line Classification: Cautious (medium confidence)
•Synopsis: Three mandatory‐tender/put events totaling ≈$275 million fall between Oct–Dec 2025 (Signals 11, 13, 15, 17), while a just-issued $100 million direct-placement bond ((Oklahoma Health Care Authority 2024 06 GSAFAC 0000363157; 2025-11-14)) lifts pro-forma debt and compresses liquidity that may also be needed to absorb a potential $140 million CMS-DSH settlement ((Oklahoma Health Care Authority 2024 06 GSAFAC 0000363157; 2025-11-14)). All exposures mature or can crystallise inside the next 12 months, raising near-term refinancing and cash-deployment risk under a covenant that is only a 1.10× performance floor.
Signal 10
In September 2024, the Obligated Gr oup issued Series 2024A Health System Revenue Bonds of the Oklah
Oklahoma Health Care Authority 2024 06 GSAFAC 0000363157 • 2025-11-14
Signal 16
would result in a settlement payment and adjustment to the Obligated Group’s earnings in the year of
Oklahoma Health Care Authority 2024 06 GSAFAC 0000363157 • 2025-11-14
Rationale
Baseline (Foundation Analysis)
•Structure: parity Master Indenture, performance-floor DSC covenant (1.10×) with no automatic rate reset; issuer bears revenue shortfall risk.
•Historical headroom: 3.0–5.7× DSC and 244 DCOH (FY 2020).
•Primary risks: revenue volatility and expense control; no reserve fund; liquidity is the main shock absorber.
Theme 1 – Refinancing Concentration in 4Q 2025
•Signals 11, 13, 15 reveal three separate mandatory tenders/short maturities (Series 2019A, 2020D, 2024A) that together require take-out financing or internal cash within 11-13 months. Unlike routine amortisation, these puts were not identified in the 2020 base-case and thus constitute a departure from the foundation baseline.
•(Oklahoma Health Care Authority 2024 06 GSAFAC 0000363157; 2025-11-14) layers additional remarketing risk on Series 2020B/C; failure would accelerate principal three years after a failed attempt but still increases market-access dependency.
Signal 17
In the event of a failed remarketing, the series 2020B and series 2020C bonds are subject to mandato
Oklahoma Health Care Authority 2024 06 GSAFAC 0000363157 • 2025-11-14
•Materiality path: Debt/Leverage | Liquidity. The Master Indenture offers no automatic source of funds other than system cash; therefore the risk is un-mitigated by structure.
Theme 2 – Incremental Leverage
•(Oklahoma Health Care Authority 2024 06 GSAFAC 0000363157; 2025-11-14) documents a $100 million privately placed Series 2024A borrowing. While coverage margin (≈3× vs. 1.10× covenant) preliminarily satisfies the Additional Bonds Test, it raises total bullet/put exposure in the same horizon cited above. Peer benchmarking in the foundation put debt/capital at 33 %; the new issue moves the metric modestly higher but remains within peer norms, tempering but not eliminating concern.
Signal 10
In September 2024, the Obligated Gr oup issued Series 2024A Health System Revenue Bonds of the Oklah
Oklahoma Health Care Authority 2024 06 GSAFAC 0000363157 • 2025-11-14
Theme 3 – Contingent Legal Liability
•Signals 14 and 16 confirm an unresolved CMS DSH dispute: current liability still $48 million and potential adverse settlement ≈$140 million. This was not highlighted as a baseline exposure in 2020 and therefore represents an emergent, un-budgeted drain on unrestricted cash—again funnelling through the Liquidity materiality path.
Red Flags
•Clustered 2025 puts with no identified refunding plan (Signals 11, 13, 15).
•Sizeable single-event legal exposure ((Oklahoma Health Care Authority 2024 06 GSAFAC 0000363157; 2025-11-14)) that would land on the same liquidity pool required for debt puts.
Signal 16
would result in a settlement payment and adjustment to the Obligated Group’s earnings in the year of
Oklahoma Health Care Authority 2024 06 GSAFAC 0000363157 • 2025-11-14
Signal weighting: board/issuer disclosures (Signals 10–17) outrank all other evidence and drive classification.
Signals & Trends
(Oklahoma Health Care Authority 2024 06 GSAFAC 0000363157; 2025-11-14): “The Series 2019A bonds are subject to a mandatory tender… in December 2025” [FY-2024 FS; 2025-09; note 9]
Signal 11
The Series 2019A bonds are subject to a mandatory tender by the holder of the bonds in December 202
Oklahoma Health Care Authority 2024 06 GSAFAC 0000363157 • 2025-11-14
Debt/Leverage | Liquidity – $95 million put in 13 months; new compared with 2020 baseline; heightens short-term cash call.
(Oklahoma Health Care Authority 2024 06 GSAFAC 0000363157; 2025-11-14): “The Series 2020D bonds are subject to a mandatory tender… in October 2025” [FY-2024 FS; 2025-09; note 9]
Signal 15
The Series 2020D bonds are subject to a mandatory tender by the holder of the bonds in October 2025,
Oklahoma Health Care Authority 2024 06 GSAFAC 0000363157 • 2025-11-14
Debt/Leverage | Liquidity – $80 million exposure inside 12 months; compounds refinancing stack.
(Oklahoma Health Care Authority 2024 06 GSAFAC 0000363157; 2025-11-14): “2024 Bonds… fixed 3.68% with a maturity date of October 2025” [FY-2024 FS; 2025-09; note 9]
Signal 13
The 2024 Bonds were purchase d by a si ngle financial institution in a direct, private placement tra
Oklahoma Health Care Authority 2024 06 GSAFAC 0000363157 • 2025-11-14
Debt/Leverage | Liquidity – Direct placement ($100 million) requires bullet repayment or rollover in same window; private mode limits market flexibility.
(Oklahoma Health Care Authority 2024 06 GSAFAC 0000363157; 2025-11-14): “In the event of a failed remarketing, the Series 2020B and 2020C bonds are subject to mandatory redemption” [FY-2024 FS; 2025-09; note 9]
Signal 17
In the event of a failed remarketing, the series 2020B and series 2020C bonds are subject to mandato
Oklahoma Health Care Authority 2024 06 GSAFAC 0000363157 • 2025-11-14
Debt/Leverage – Adds event risk that could accelerate ≈$100 million beyond scheduled amortisation; structural protections do not offset.
(Oklahoma Health Care Authority 2024 06 GSAFAC 0000363157; 2025-11-14): “In September 2024, the Obligated Group issued… $100,000,000” [FY-2024 FS; 2025-09; note 9]
Signal 10
In September 2024, the Obligated Gr oup issued Series 2024A Health System Revenue Bonds of the Oklah
Oklahoma Health Care Authority 2024 06 GSAFAC 0000363157 • 2025-11-14
Debt/Leverage – Incremental borrowing modestly elevates leverage; within ABT but enlarges upcoming refinancing wall.
(Oklahoma Health Care Authority 2024 06 GSAFAC 0000363157; 2025-11-14): “…would result in a settlement… approximately $140,000,000” [FY-2024 FS; 2025-09; note 12]
Signal 16
would result in a settlement payment and adjustment to the Obligated Group’s earnings in the year of
Oklahoma Health Care Authority 2024 06 GSAFAC 0000363157 • 2025-11-14
Legal/Pledge | Liquidity – Potential one-time cash hit that could cut DSC cushion below historical norms; unmitigated by rate-setting authority.
(Oklahoma Health Care Authority 2024 06 GSAFAC 0000363157; 2025-11-14): “The liability… approximately $48,300,000… June 30, 2024” [FY-2024 FS; 2025-09; note 12]
Signal 14
The liability has been reduced by these payments and is approx imately $48,300,000 and $62,200,000 o
Oklahoma Health Care Authority 2024 06 GSAFAC 0000363157 • 2025-11-14
Legal/Pledge – Existing but decreasing accrual; still material given no reserve fund.
None of the remaining signals materially alter the foundation baseline or are issuer-specific; they are therefore excluded.
Outlook
Base-case: System DSC expected to remain comfortably above the 1.10× floor, but unrestricted cash will be the sole buffer against a coincident $275 million tender wall and any DSH settlement. Absent a proactive refunding, internal liquidity could fall toward peer-median levels, narrowing headroom that underpins the historical A-category profile.
Near-term Catalysts (3-12 months)
•Management disclosure of refinancing or remarketing strategy for Series 2019A/2020D/2024A (Signals 11, 13, 15).
•Final resolution or escalation of CMS-DSH dispute (Signals 14, 16).
Downside Scenario (to Immediate Attention)
•Failure to secure committed bank lines or public-market take-out before 3Q 2025, or an adverse $140 million settlement ((Oklahoma Health Care Authority 2024 06 GSAFAC 0000363157; 2025-11-14)) drawn from cash, materially eroding DSC cushion or covenant compliance.
Signal 16
would result in a settlement payment and adjustment to the Obligated Group’s earnings in the year of
Oklahoma Health Care Authority 2024 06 GSAFAC 0000363157 • 2025-11-14
Upside Scenario (toward Stable)
•Early refunding of ≥75 % of 2025 put exposure with long-dated fixed-rate debt, or negotiated settlement of the DSH dispute at materially less than the recorded reserve, preserving liquidity.
Appendix
[1] INTEGRIS Health and Affiliates Consolidated Financial Statements; FY-2024; note 9 (debt) & note 12 (contingencies).
[2] Offering Memorandum, INTEGRIS Baptist Medical Center, Inc. Taxable Bonds, Series 2020A; Oct 2020.
Data QA Notes: Current rating disclosed as “NR”, whereas foundation analysis cited S&P A/Moody’s A3 (2020). No updated audited DSC, liquidity or cash-flow data beyond FY-2024 excerpts; therefore coverage headroom quantified to FY-2020 baseline only. Limited visibility into size and terms of Series 2019A/2020D outstanding.
Full Signal Details: see <<<CLEANED_SIGNALS>>> entries 10–17.